Obama Gets "F" on Medical Marijuana Report Card
SAN FRANCISCO, CA -- The patient advocacy group Americans for Safe Access (ASA) issued a report card today giving President Obama a failing grade for his record on medical marijuana.
The report card highlights broken promises, half-measures, and a general failure by the Obama Administration to address medical marijuana as a national public health issue. Citing ongoing federal raids, the report card accused the government of undermining local and state medical marijuana laws, and urged the Obama administration to develop a comprehensive federal policy that truly curbs enforcement. The report card also calls for expanded research and the reclassification marijuana from its status as a dangerous drug with no medical value.
"While the prevailing public perception is that President Obama has addressed the issue of medical cannabis," stated the report card, "that perception could not be further from the truth." The report card was issued in conjunction with protests organized by ASA in San Francisco, as President Obama launched his re-election campaign. Patients and supporters rallied at 8am this morning outside of the St. Regis Hotel, where a fundraiser was being held, carrying signs that read, "We're Sick and Tired," "Reschedule Cannabis Now," and "Federal Protection Not Federal Prosecution."
"Patients are sick and tired of being marginalized and living in fear of the federal government," said Steph Sherer, Executive Director of ASA. "It's time to push politics aside, recognize the plight of patients across the country, and properly address medical marijuana as the public health issue that it is."
Despite an October 2009 Justice Department memorandum aimed at de-emphasizing federal enforcement in medical marijuana states, the Obama administration has since conducted nearly 100 aggressive, SWAT-style raids on patients, growers, dispensaries and laboratories in California, Colorado, Michigan, Montana and Nevada. These raids have so far resulted in nearly 30 new federal prosecutions. President Obama has also continued to vigorously prosecute his predecessor's federal cases, rather than turning them over to be adjudicated in state courts. Most recently, Obama's Justice Department threatened public officials from Washington State with criminal prosecution if they implement a medical marijuana distribution system designed and approved by the legislature.
The report card also points out federal half-measures related to public housing, veterans affairs, banking and the Internal Revenue Service. A reluctance by the federal government to adequately address the issue of medical marijuana has instead created a patchwork of confusing and often contradictory policies. Vast discretionary powers are given to landlords in deciding whether to evict patients from public housing, just as discretion is given to veterans' physicians in deciding whether to deny pharmaceutical medication to qualified patients. In the financial world, the government is instructing large banks like CitiCorp, Wells Fargo and Bank of America to purge even state-compliant medical marijuana businesses, and the Internal Revenue Service is conducting dozens of audits in an effort to shut down licensed dispensaries.
In addition to calling for the reclassification of medical marijuana from its current status as a Schedule I substance, and an end to federal raids, the comprehensive policy being sought by advocates also includes greater safeguards for patients against housing and employment discrimination. With the aim of repairing an onerous research approval process and shifting focus from studies on marijuana's abuse potential to its therapeutic benefits, advocates are calling for expanded investment into research.
Sign up for the OV Daily Newsletter
Sign-Up Now for the Opposing Views Daily Newsletter
Sign up for the OV Daily Newsletter
The following text is taken directly from the US government's National Cancer Institute website: http://www.cancer.gov/cancertopics/pdq/cam/cannabis/healthprofessional/page4
* ANTI-TUMOR EFFECTS -Sadly, the first three paragraphs were removed on March 28th 2011 shortly after media attention:
http://www.americanindependent.com/176139/first-federal-agency-to-acknowledge-medical-marijuana-removes-anti-tumor-information-from-database
Here's an image of the original entry: http://images.americanindependent.com/NCI_Cannabis.png
One study in mice and rats suggested that cannabinoids may have a protective effect against the development of certain types of tumors. During this 2-year study, groups of mice and rats were given various doses of THC by gavage. A dose-related decrease in the incidence of hepatic adenoma tumors and hepatocellular carcinoma was observed in the mice. Decreased incidences of benign tumors (polyps and adenomas) in other organs (mammary gland, uterus, pituitary, testis, and pancreas) were also noted in the rats. In another study, delta-9-THC, delta-8-THC, and cannabinol were found to inhibit the growth of Lewis lung adenocarcinoma cells in vitro and in vivo. In addition, other tumors have been shown to be sensitive to cannabinoid-induced growth inhibition.
Cannabinoids may cause antitumor effects by various mechanisms, including induction of cell death, inhibition of cell growth, and inhibition of tumor angiogenesis and metastasis. Cannabinoids appear to kill tumor cells but do not affect their nontransformed counterparts and may even protect them from cell death. These compounds have been shown to induce apoptosis in glioma cells in culture and induce regression of glioma tumors in mice and rats. Cannabinoids protect normal glial cells of astroglial and oligodendroglial lineages from apoptosis mediated by the CB1 receptor.
In an in vivo model using severe combined immunodeficient mice, subcutaneous tumors were generated by inoculating the animals with cells from human non-small cell lung carcinoma cell lines. Tumor growth was inhibited by 60% in THC-treated mice compared with vehicle-treated control mice. Tumor specimens revealed that THC had antiangiogenic and antiproliferative effects.
* ANTI-INFLAMMATORY EFFECTS
In addition, both plant-derived and endogenous cannabinoids have been studied for anti- inflammatory effects. A mouse study demonstrated that endogenous cannabinoid system signaling is likely to provide intrinsic protection against colonic inflammation. As a result, a hypothesis that phytocannabinoids and endocannabinoids may be useful in the prevention and treatment of colorectal cancer has been developed.
* ANTIVIRAL PROPERTIES
Another study has shown delta-9-THC is a potent and selective antiviral agent against Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8. The researchers concluded that additional studies on cannabinoids and herpesviruses are warranted, as they may lead to the development of drugs that inhibit the reactivation of these oncogenic viruses. Subsequently, another group of investigators reported increased efficiency of KSHV infection of human dermal microvascular epithelial cells in the presence of low doses of delta-9-THC.
Appetite Stimulation
* APPETITE STIMULATOR
Many animal studies have previously demonstrated that delta-9-THC and other cannabinoids have a stimulatory effect on appetite and increase food intake. It is believed that the endogenous cannabinoid system may serve as a regulator of feeding behavior. The endogenous cannabinoid anandamide potently enhances appetite in mice. Moreover, CB1 receptors in the hypothalamus may be involved in the motivational or reward aspects of eating.
Analgesia
* AS A PAIN KILLER
Understanding the mechanism of cannabinoid-induced analgesia has been increased through the study of cannabinoid receptors, endocannabinoids, and synthetic agonists and antagonists. The CB1 receptor is found in both the central nervous system (CNS) and in peripheral nerve terminals. Similar to opioid receptors, increased levels of the CB1 receptor are found in sections of the brain that regulate nociceptive processing. CB2 receptors, located predominantly in peripheral tissue, exist at very low levels in the CNS. With the development of receptor-specific antagonists, additional information about the roles of the receptors and endogenous cannabinoids in the modulation of pain has been obtained.
Cannabinoids may also contribute to pain modulation through an anti-inflammatory mechanism; a CB2 effect with cannabinoids acting on mast cell receptors to attenuate the release of inflammatory agents, such as histamine and serotonin, and on keratinocytes to enhance the release of analgesic opioids has been described.
Here are just some of the many studies the Feds wish they'd never commissioned:
06) OOPS, MARIJUANA MAY PREVENT CANCER (PART 1):
Federal researchers implanted several types of cancer , including leukemia and lung cancers, in mice, then treated them with cannabinoids (unique, active components found in marijuana). THC and other cannabinoids shrank tumors and increased the mice's lifespans. Munson, AE et al. Antineoplastic Activity of Cannabinoids. Journal of the National Cancer Institute. Sept. 1975. p. 597-602.
07) OOPS, MARIJUANA MAY PREVENT CANCER, (PART 2):
In a 1994 study the government tried to suppress, federal researchers gave mice and rats massive doses of THC, looking for cancers or other signs of toxicity. The rodents given THC lived longer and had fewer cancers, "in a dose-dependent manner" (i.e. the more THC they got, the fewer tumors). NTP Technical Report On The Toxicology And Carcinogenesis Studies Of 1-Trans- Delta-9-Tetrahydrocannabinol, CAS No. 1972-08-3, In F344/N Rats And B6C3F Mice, Gavage Studies. See also, "Medical Marijuana: Unpublished Federal Study Found THC-Treated Rats Lived Longer, Had Less Cancer," AIDS Treatment News no. 263, Jan. 17, 1997.
08) OOPS, MARIJUANA MAY PREVENT CANCER (PART 3):
Researchers at the Kaiser-Permanente HMO, funded by NIDA, followed 65,000 patients for nearly a decade, comparing cancer rates among non-smokers, tobacco smokers, and marijuana smokers. Tobacco smokers had massively higher rates of lung cancer and other cancers. Marijuana smokers who didn't also use tobacco had no increase in risk of tobacco-related cancers or of cancer risk overall. In fact their rates of lung and most other cancers were slightly lower than non-smokers, though the difference did not reach statistical significance. Sidney, S. et al. Marijuana Use and Cancer Incidence (California, United States). Cancer Causes and Control. Vol. 8. Sept. 1997, p. 722-728.
09) OOPS, MARIJUANA MAY PREVENT CANCER (PART 4):
Donald Tashkin, a UCLA researcher whose work is funded by NIDA, did a case-control study comparing 1,200 patients with lung, head and neck cancers to a matched group with no cancer. Even the heaviest marijuana smokers had no increased risk of cancer, and had somewhat lower cancer risk than non-smokers (tobacco smokers had a 20-fold increased Lung Cancer risk). Tashkin D. Marijuana Use and Lung Cancer: Results of a Case-Control Study. American Thoracic Society International Conference. May 23, 2006.
10) MARIJUANA DOES HAVE GREAT MEDICAL VALUE:
In response to passage of California's medical marijuana law, the White House had the Institute of Medicine (IOM) review the data on marijuana's medical benefits and risks. The IOM concluded, "Nausea, appetite loss, pain and anxiety are all afflictions of wasting, and all can be mitigated by marijuana." The report also added, "we acknowledge that there is no clear alternative for people suffering from chronic conditions that might be relieved by smoking marijuana, such as pain or AIDS wasting." The government's refusal to acknowledge this finding caused co-author John A. Benson to tell the New York Times that the government "loves to ignore our report … they would rather it never happened." Joy, JE, Watson, SJ, and Benson, JA. Marijuana and Medicine: Assessing the Science Base. National Academy Press. 1999. p. 159. See also, Harris, G. FDA Dismisses Medical Benefit From Marijuana. New York Times. Apr. 21, 2006
Here are just some of the many studies the Feds wish they'd never commissioned:
01) MARIJUANA USE HAS NO EFFECT ON MORTALITY:
A massive study of California HMO members funded by the National Institute on Drug Abuse (NIDA) found marijuana use caused no significant increase in mortality. Tobacco use was associated with increased risk of death. Sidney, S et al. Marijuana Use and Mortality. American Journal of Public Health
. Vol. 87 No. 4, April 1997. p. 585-590. Sept. 2002.
02) HEAVY MARIJUANA USE AS A YOUNG ADULT WON'T RUIN YOUR LIFE:
Veterans Affairs scientists looked at whether heavy marijuana use as a young adult caused long-term problems later, studying identical twins in which one twin had been a heavy marijuana user for a year or longer but had stopped at least one month before the study, while the second twin had used marijuana no more than five times ever. Marijuana use had no significant impact on physical or mental health care utilization, health-related quality of life, or current socio-demographic characteristics. Eisen SE et al. Does Marijuana Use Have Residual Adverse Effects on Self-Reported Health Measures, Socio-Demographics or Quality of Life? A Monozygotic Co-Twin Control Study in Men. Addiction. Vol. 97 No. 9. p.1083-1086. Sept. 1997
03) THE "GATEWAY EFFECT" MAY BE A MIRAGE:
Marijuana is often called a "gateway drug" by supporters of prohibition, who point to statistical "associations" indicating that persons who use marijuana are more likely to eventually try hard drugs than those who never use marijuana - implying that marijuana use somehow causes hard drug use. But a model developed by RAND Corp. researcher Andrew Morral demonstrates that these associations can be explained "without requiring a gateway effect." More likely, this federally funded study suggests, some people simply have an underlying propensity to try drugs, and start with what's most readily available. Morral AR, McCaffrey D and Paddock S. Reassessing the Marijuana Gateway Effect. Addiction. December 2002. p. 1493-1504.
04) PROHIBITION DOESN'T WORK:
The White House had the National Research Council examine the data being gathered about drug use and the effects of U.S. drug policies. NRC concluded, "the nation possesses little information about the effectiveness of current drug policy, especially of drug law enforcement." And what data exist show "little apparent relationship between severity of sanctions prescribed for drug use and prevalence or frequency of use." In other words, there is no proof that prohibition - the cornerstone of U.S. drug policy for a century - reduces drug use. National Research Council. Informing America's Policy on Illegal Drugs: What We Don't Know Keeps Hurting Us. National Academy Press, 2001. p. 193.
05) PROHIBITION MAY CAUSE THE "GATEWAY EFFECT"?): U.S. and Dutch researchers, supported in part by NIDA, compared marijuana users in San Francisco, where non-medical use remains illegal, to Amsterdam, where adults may possess and purchase small amounts of marijuana from regulated businesses. Looking at such parameters as frequency and quantity of use and age at onset of use, they found the following: Cannabis (Marijuana) use in San Francisco was 3 times the prevalence found in the Amsterdam sample. And lifetime use of hard drugs was significantly lower in Amsterdam, with its "tolerant" marijuana policies. For example, lifetime crack cocaine use was 4.5 times higher in San Francisco than Amsterdam. Reinarman, C, Cohen, PDA, and Kaal, HL. The Limited Relevance of Drug Policy: Cannabis in Amsterdam and San Francisco. American Journal of Public Health. Vol. 94, No. 5. May 2004. p 836-842.